Genprex, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Genprex, Inc. (GNPX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.00 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-30
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-09-30 was $18.00, a 1108.05% increase year-over-year.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $0.00.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $30.14, a 65.14% decline from fiscal 2022.
- Genprex, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $86.45, a 1929.34% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-30 | |||||
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | |||||
| 2024-06-30 | $0.00 10-Q · filed 2024-11-13 | |||||
| 2024-03-31 | $0.00 10-Q · filed 2024-11-13 | |||||
| 2023-12-31 | $30.14 10-K · filed 2025-04-01 | |||||
| 2023-09-30 | $18.00 10-Q · filed 2024-11-13 | $0.45 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $34.17 10-Q · filed 2024-11-13 | $0.85 10-Q · filed 2023-08-21 | ||||
| 2023-03-31 | $57.23 10-Q · filed 2024-11-13 | $1.43 10-Q · filed 2023-05-22 | ||||
| 2023-03-30 | $1.43 10-Q · filed 2023-08-21 | |||||
| 2022-12-31 | $86.45 10-K · filed 2024-04-01 | $2.16 10-K · filed 2023-03-31 | ||||
| 2022-09-30 | $1.49 10-Q · filed 2023-11-14 | $2.18 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $1.62 10-Q · filed 2023-11-14 | $1.59 10-Q · filed 2023-08-21 | $2.18 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | $2.30 10-Q · filed 2023-11-14 | |||||
| 2021-12-31 | $4.26 10-K · filed 2023-03-31 | |||||
| 2021-09-30 | $4.26 10-Q · filed 2021-11-15 | |||||
| 2021-06-30 | $6.01 10-Q · filed 2021-08-13 | |||||
| 2021-03-31 | $5.43 10-Q · filed 2021-05-17 | |||||
| 2020-12-31 | $2.87 10-K · filed 2022-03-30 | |||||
| 2020-09-30 | $2.78 10-Q · filed 2020-11-12 | |||||
| 2020-06-30 | $2.01 10-Q · filed 2020-08-11 | |||||
| 2020-03-31 | $2.00 10-Q · filed 2020-05-14 | |||||
| 2019-12-31 | $1.48 10-K · filed 2021-03-26 | |||||
| 2019-09-30 | $1.60 10-Q · filed 2019-11-14 | |||||
| 2019-06-30 | $1.60 10-Q · filed 2019-08-13 | |||||
| 2019-03-31 | $1.60 10-Q/A · filed 2019-05-20 | |||||
| 2018-12-31 | $6.21 10-K · filed 2020-03-30 | |||||
| 2018-09-30 | $9.80 10-Q · filed 2018-11-14 | |||||
| 2018-06-30 | $9.80 10-Q · filed 2018-08-14 | |||||
| 2017-12-31 | $0.00 10-K · filed 2019-04-01 | |||||
| 2016-12-31 | $1.76 10-K · filed 2018-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |